Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Optive Fusion vs Optive in Dry Eye Disease
NCT01664949Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2013
- Primary completion
- May 2014
- Modality
- Polymer-based Nanoparticles
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of hyaluronic acid sodium salt in dry eye disease (DED) (2 arms), sponsored by Allergan. Primary endpoint: Ocular Surface Disease Index at Day 90. Started Jan 2013; status: completed.
02
Drugs
hyaluronic acid sodium salt
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT01664949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01664949.